In this webinar, you will learn: Explore how REpAb can sequence antibodies from the plasma of a naturally exposed human, identifying functional antibodies in circulation. Review study findings showing antibodies with broad inhibitory activity against diverse malaria variants, validated through structural and functional analysis. Learn how REpAb can be applied to study and [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
In this webinar, you will learn: How to efficiently filter out non-specific binders early on to focus only on antibodies with true functional potential. Strategies to isolate highly specific anti-idiotype antibodies that avoid cross-reactivity with natural IgGs. The benefits of combining advanced enrichment techniques with proteomics to discover both blocking (type 1) [...]
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Written by: Jenna Kerry, MSc Published: December 20, 2024 Contents What is Phage Display? How Does Phage Display Work? Phage Display Technology Advantages Phage Display Technology Limitations The Future of Phage Display Technology Overcoming Limitations of Phage Display Antibody Discovery What is Phage Display? Over [...]
Written by: Genya Gorshtein, MSc Published: December 12, 2024 Contents Introduction B Cells and Their Receptors Antibodies in Serum How Do You Discover Antibodies From Serum? Introduction While B cells play a crucial role in recognizing antigens and initiating immune responses, their differentiation into [...]
Written by: Genya Gorshtein, MSc Published: December 12, 2024 Contents Introduction BCR and Single B Cell Sequencing for Antibody Discovery Antibody Discovery through De Novo Sequencing of Serum Antibodies Proteogenomics: A Complimentary Approach Antibody Discovery With Rapid Novor Introduction B cell sequencing has long [...]
Written by: Jenna Kerry, MSc Published: November 6, 2024 Contents Why Humanize Antibodies? What is Antibody Humanization? Antibody Humanization Techniques Current Challenges of Antibody Humanization The Future of Human Antibody Therapeutics Fully Human Antibody Discovery / Human Antibody Discovery From Human Serum Why Humanize Antibodies? [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Written by: Jenna Kerry, MSc Published: September 17, 2024 Contents Introduction Agonistic Antibody Mechanism of Action Agonistic Antibody Development Challenges Optimizing Agonistic Antibodies Agonistic Antibody Development Introduction In the last decade, immunotherapy has rapidly transformed treatments for cancer, autoimmune disorders, and infectious diseases. While the [...]
Written by: Genya Gorshtein, MSc Published: August 26, 2024 Contents Introduction Advantages of Antibody Discovery In Diverse Species Unique Features of Antibodies from Diverse Hosts Antibody Discovery Platforms for Diverse Hosts Introduction The historical use of mice for monoclonal antibody generation has been driven [...]
Written by: Jenna Kerry, MSc Published: August 14, 2024 Contents What are Antagonistic Antibodies? How do Antagonistic Antibodies Work? Antagonistic Antibody Opportunities Antagonistic Antibody Obstacles Antibody Discovery Platform for Antagonistic Antibodies What are Antagonistic Antibodies? Antagonistic antibodies are a monoclonal antibody that bind to and [...]
Principal Scientist in Polyclonal Antibody Sequencing Dr. Thierry Le Bihan joined Rapid Novor as a Principal Scientist in 2018, tasked with leading a multidisciplinary team to develop a polyclonal antibody sequencing platform. Thierry brought extensive proteomics and mass spectrometry expertise from his previous roles as Director of Proteomics at The Campbell Family Institute [...]
This paper is now published in Nature Communications! Le Bihan, T., Nunez de Villavicencio Diaz, T., Reitzel, C. et al. De novo protein sequencing of antibodies for identification of neutralizing antibodies in human plasma post SARS-CoV-2 vaccination. Nat Commun 15, 8790 (2024). https://doi.org/10.1038/s41467-024-53105-8 In this webinar, you will: Explore how using a [...]
Written by: Vanessa Yoon Calvelo, PhD Published: June 6, 2023 Updated: July 7, 2024 Contents Introduction Early Discovery and Development of Therapeutic Antibodies Target Identification and Validation Antibody Discovery and Expression Lead Characterization and Selection Lead Engineering and Optimization Candidate Selection and Downstream Characterization Introduction [...]
In this webinar, you will learn: How AI and HDX-MS are applied in screening, epitope mapping, and selecting neutralizing antibodies against SARS-Cov-2. The predictive capabilities of AI computational modeling and its validation and refinement by high-resolution HDX-MS. How the integration of AI with HDX-MS informs antibody characterization for the accelerated development of therapeutic [...]
Written by: Genya Gorshtein, MSc Published: April 3, 2024 Contents Introduction Membrane Proteins are Difficult Antigens Strategies for Utilizing Membrane Proteins as Antigens in Antibody Discovery In Vivo Antibody Discovery Using Mass Spectrometry Introduction Membrane proteins orchestrate a wide range of cellular functions, such [...]
Authors: Teresa Nunez de Villavicencio Diaz, Kyle Suttill, Chelsea Reitzel, Rosalin Dubois, Qixin Liu, Marko Jović, Dominic Narang, Thierry Le Bihan, Bin Ma Published: Nov 13, 2023, Revised: Nov 25, 2025 Abstract In this study, we demonstrate a novel approach for alpaca antibody discovery that bypasses traditional B [...]
Written by: Jenna Kerry, MSc Published: October 25, 2023 Contents Introduction What is Affinity Maturation? How Does Somatic Hypermutation Work? Applications of Affinity Maturation De Novo Proteomic Sequencing of Antibodies Introduction The immune system is a complex system responsible for protecting organisms from various [...]
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
In this webinar, you will learn: About the challenges commonly encountered in antibody discovery campaigns, including non-functional antibodies, limited diversity, developability issues, and immunogenicity. How to de-risk antibody discovery campaigns, while balancing speed and spend Discover how a proteomics and mass spectrometry-based approach to antibody discovery, utilizing REpAb polyclonal sequencing, presents [...]
By conducting an in-depth analysis of non-antigen immunized sheep Ig repertoires via NGS, this data provides further insight into the adaptive immunity of sheep and lays a foundation for future work on immunogenetics and ovine antibody drug development.
The great debate on the use of in vivo versus in vitro sources and strategies for antibody discovery and generation continues to thrive among antibody research groups. On one side of the debate is the argument for non-animal-derived antibodies due to the technical advancements of current in vitro technologies, and the moral obligation to reduce animal usage. On the other side of the debate is the counterargument for animal-derived antibodies due to their better performance in affinity, specificity, and reduced immunogenicity risk.
In this SPR webinar, you will learn: How SPR works and its unique advantages for kinetic analysis of antibody-antigen interactions Applications of SPR in antibody discovery Functionality of SPR in antibody characterization Abstract Due to their ability to bind biomolecules specifically and tightly, antibodies are highly sought [...]
Written by: Vanessa Yoon Calvelo, PhD Published: July 11, 2022 Contents What is Gene Therapy? What are Adeno-Associated Viruses? Engineering of AAVs for Gene Therapy Engineering AAVs for Improved Transduction Engineering AAVs for Improved Immunogenicity De Novo Protein Sequencing Applications in AAV Characterization and Development What is Gene [...]
Written by: Vanessa Yoon Calvelo, PhD Published: June 13, 2022 Contents What is CAR-T Cell Therapy? CAR Structure and Function CAR-T Cell Development Engineering Strategies for CAR-T Cells De Novo Protein Sequencing Applications in CAR-T Cell Development What is CAR-T Cell Therapy? The infusion of T cells [...]
The most straightforward solution would be to determine sequences of the dominating antibody forms in a polyclonal mixture to enable recombinant antibody generation and ensure reproducibility. This was recently made possible by the development of polyclonal antibody sequencing technology, which will be reviewed in this article.
Hendra virus (HeV) and Nipah virus (NiV) are types of Henipaviruses (HNVs) that originated in bats and can infect the human respiratory system with detrimental consequences. As enveloped, single-stranded RNA viruses, HeV and NiV use attachment (G) and fusion (F) glycoproteins on the envelope membrane to enter host cells. So far, there are no approved therapeutics or vaccines to combat the viruses in humans.
The ongoing pandemic has reinforced the need for in vitro diagnostics to globally surveille emerging pathogens and provide better medical care. In particular, immunoassays are favoured due to their affordability, ease, and speed. Nevertheless, the combination of rapidly evolving pathogens, and more complex diseases resulting from increasing life expectancy worldwide require more sensitive and specific immunoassays in the nick of time. To increase sensitivity, immunoassay development can benefit from exploiting industry-leading technologies such as de novo protein sequencing.
Circulating in blood is a multitude of biologically important antibodies. These pools of polyclonal antibodies (pAb) are invaluable sources for drug discovery against various diseases, and for the development of robust immunoreagents for diagnostics, and research.
Research Challenges in Veterinary Medicine Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment.
Written by: Yuning Wang, PhD Updated: January 18, 2023 (Published: January 21, 2022) Contents Discovery of Camelid Antibodies What are Camelid Antibodies? Structure of Camelid Antibodies and Nanobodies Advantages of Camelid Antibodies and Nanobodies Camelid Antibodies and Nanobodies for Therapeutic and Research Applications How are Camelid Antibodies [...]
Over the past several years Rapid Novor has been developing the world's best antibody protein sequencing platform, with over 2700 monoclonal antibodies and proteins sequenced. In 2020, they unveiled their most advanced technology to date- REpAb® polyclonal antibody sequencing. The platform combines the world's best protein sequencing technology and NGS to comprehensively mine the antigen specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patient's blood.
Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply
Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.
The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.
The protein sequence is key to understanding the function of a protein target and is critical to therapeutic and diagnostic development. This is particularly important for antibodies whose code diversity and glycosylation impact both function, and stability.
Over the past 5 years Rapid Novor has perfected monoclonal antibody sequencing, and is now sequencing mAbs from polyclonal mixtures using REpAb®. After successfully launching their proteogenomics based sequencing technology to deconvolute the immune response, the team has further evolved the technology and has derived the most abundant mAb sequences directly from rabbit blood using only proteomics. The talk will surround the development, progress and use cases for REpAb®.
Over the past several years Rapid Novor has been developing the world’s best antibody protein sequencing platform, sequencing over 2700 monoclonal antibodies and proteins. In 2020, they unveiled their most advanced technology to date - REpAb® polyclonal antibody sequencing. The platform combines the world’s best protein sequencing technology and NGS to comprehensively mine the antigen-specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patients’ blood.
Mouse monoclonal antibodies (mAbs) are highly attractive for manipulation for therapeutic applications as their manufacturing is relatively easy and well-established compared to mAbs derived from larger animal models. However, they also pose several challenges which limit their use as therapeutic agents.
Recombinant Monoclonal Antibodies (rAbs) are highly reproducible, customizable and pure alternatives to the traditional antibodies produced by hybridomas. Get the antibody protein sequence, either by DNA sequencing or the de novo protein sequencing technology, you can rest assured that you can have the exact antibody made recombinantly anytime in the future.